February 28th, 22
Social Survey Research Information Co., Ltd.
Social Survey Research Information Co., Ltd.
Press Release
Analysis of trends in the needs for new drugs with PatientsMap data
Dissatisfaction with existing cancer drugs, and dissatisfaction with the absence of treatments for rare and intractable conditions
Differing trends clarified
Social Survey Research Information Co., Ltd. and M3, Inc. have conducted an analysis to identify the reasons behind why physicians desire new drugs to be developed for certain conditions, using PatientsMap 2021JP (Japan 2021 version) data from physician surveys.
Table 1 shows the percentages of physicians by point of dissatisfaction with existing treatments for the top 10 conditions for which physicians who see at least one patient for each condition expressed a desire for new drugs to be developed.The top conditions for which new drugs were desired were retinitis pigmentosa (percentage of applicable physicians: 78.5%), leiomyosarcoma (68.2%), mesothelioma (66.2%), sporadic inclusion body myositis (60.8%), biliary tract cancer (58.9%), and treatment-resistant schizophrenia (56.5%).
For these conditions, “efficacy” and “absence of treatments” were the primary points of dissatisfaction with existing treatments. Conditions for which “efficacy” was a point of dissatisfaction were leiomyosarcoma (61.7%), mesothelioma (62.3%), biliary tract cancer (51.8%), and treatment-resistant schizophrenia (48.2%). Meanwhile, conditions for which “absence of treatments” was a point of dissatisfaction were retinitis pigmentosa (48.1%) and sporadic inclusion body myositis (36.2%).
The results above once again confirm that physicians desire new drugs for two main types of conditions: those for which there are treatments already available but better treatments are desired, and those for which a new drug is desired because there is an absence of treatments to begin with. It can be inferred that dissatisfaction with existing drugs is behind the desire for new drugs for cancer conditions, and dissatisfaction with the absence of treatments is behind the desire for new drugs for rare and intractable conditions.
PatientsMap is an extensive database that annually surveys more than 20,000 physicians on percentages of patients seen, number of patients, unmet medical needs (desires for the development of new drugs), and the real sales rep and e-detailing activities of pharmaceutical companies for approximately 400 conditions, with surveys having been conducted continuously with the same survey frame for over 10 years since 2010.
As option data for the Japan 2021 version, respondents were also surveyed on reasons for desires for new drugs (points of dissatisfaction with existing treatments) and percentages of patients for whom respondents desire new drugs.
(Table 1) Top 10 conditions in terms of desires for new drugs and dissatisfaction with existing treatments among physicians who see patients with each condition
*Percentages shown in the table are based on the denominator of physicians who see at least one patient with each condition
| Rank | Condition | Percentage of physicians who desire new drugs | Percentage of physicians by point of dissatisfaction with existing treatments | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Efficacy | Safety | Cost burden | Dosage and administration | Dosage form | Absence of treatments | ||||
| 1 | Retinitis pigmentosa | n=158 | 78.5% | 38.6% | 4.4% | 3.8% | 2.5% | 1.3% | 48.1% |
| 2 | Leiomyosarcoma | n=107 | 68.2% | 61.7% | 15.9% | 8.4% | 0.9% | 1.9% | 19.6% |
| 3 | Abnormal very-long-chain fatty acid metabolism | n=6* | 66.7% | 33.3% | 0.0% | 0.0% | 0.0% | 0.0% | 50.0% |
| 4 | Primary hyperoxaluria | n=3* | 66.7% | 33.3% | 33.3% | 0.0% | 0.0% | 33.3% | 33.3% |
| 5 | Mesothelioma | n=154 | 66.2% | 62.3% | 16.2% | 13.6% | 1.3% | 0.6% | 9.1% |
| 6 | Sporadic inclusion body myositis | n=130 | 60.8% | 29.2% | 3.1% | 3.8% | 0.8% | 1.5% | 36.2% |
| 7 | Niemann-Pick disease type C | n=10* | 60.0% | 30.0% | 0.0% | 10.0% | 0.0% | 0.0% | 20.0% |
| 8 | Biliary tract cancer | n=870 | 58.9% | 51.8% | 10.8% | 6.8% | 1.1% | 1.0% | 10.0% |
| 9 | Treatment-resistant schizophrenia | n=1,055 | 56.5% | 48.2% | 18.9% | 3.6% | 2.3% | 3.4% | 6.9% |
| 10 | Non-dystrophic myotonia | n=16* | 56.3% | 25.0% | 6.3% | 12.5% | 6.3% | 6.3% | 25.0% |
| 10 | Cockayne syndrome | n=16* | 56.3% | 18.8% | 6.3% | 0.0% | 0.0% | 0.0% | 43.8% |
Data source: Needs for new drugs option data, PatientsMap2021JP
*The cells with the highest percentages of physicians by point of dissatisfaction with existing treatments for each condition are colored yellow, and the cells with the second highest percentages are colored green.
*Small samples are provided for reference only.
Outline of PatientsMap 2021JP
A survey was conducted of m3 panel physicians.
Target respondents: M3-registered physicians
Method: Online survey
Fieldwork period: April 21, 2021 to August 14, 2021
Sample size: 20,201
Number of conditions surveyed: 442 diseases
Survey topic: Total number of patients (in the past month)
Number of patients seen by condition (in the past month)
Number of patients who were prescribed drugs by condition (in the past month)
Diseases for which new drugs are desired
Reasons why new drugs are desired by condition (Dissatisfaction with existing drugs)
Percentage of patients for whom respondents desire new drugs by condition (Percentage of patients who desire new drugs)
Manufacturers whose sales reps visited respondents (in the past month)
Manufacturers from which respondents received information via the Internet/from sales reps (in the past month)
Manufacturers from which respondents received information via the internet/not from sales reps (in the past month)
Trusted manufacturers
In Japan, this service will be jointly provided by Social Survey Research Information Co., Ltd. and M3, Inc.
■ Contact Information
Social Survey Research Information Co., Ltd.
E-mail: patientsmap@ssri.com
■ Social Survey Research Information Co., Ltd.
Established: April 1982
Capital: 27 million JPY
President & CEO: Takashi Makita
Number of employees: 137
Location: Head Office
NMF Shinjuku East Bldg. 2F, 3F
10-5 Tomihisacho, Shinjuku-ku, Tokyo 162-0067 JAPAN
Osaka office:
Daimei Bldg. 4F, 4-6-3 Hirano-cho, Chuo-ku, Osaka 541-0046
Affiliate companies: PD Research Co., Ltd.
MDB Co.
SSRI China Co., Ltd. (overseas subsidiary)
SSRI Asia Pacific Co., Ltd. (overseas subsidiary)
HIMA Research (overseas affiliate)
URL: http://www.ssri.com/
■ M3, Inc.
Established: September 2000
Capital: 29.036 billion JPY (as of March 31, 2021)
Representative Director: Itaru Tanimura
Number of employees, consolidated: 8,249 (as of March 31, 2021)
Location: Akasaka Intercity 10F 1-11-44 Akasaka, Minato-ku, Tokyo
URL: https://corporate.m3.com/